Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTNNB1 | P35222 | 1/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.49 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | ACP3 | P15309 | 1/20 | 0.43 |
| ▸ | ADRB2 | P07550 | 4/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | CTSS | P25774 | 1/20 | 0.41 |
| ▸ | CTSK | P43235 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | PIP4K2A | P48426 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15096099 | 1.00 | CTNNB1 (0.49) | CTNNB1TDP1CYP1A2CYP2C19CYP2C9 | |
| SCHEMBL15096098 | 1.00 | CTNNB1 (0.49) | CTNNB1TDP1CYP1A2CYP2C19CYP2C9 | |
| SCHEMBL31450593 | 1.00 | CTNNB1 (0.49) | CTNNB1TDP1CYP1A2CYP2C19CYP2C9 | |
| SCHEMBL11567192 | 0.82 | CTNNB1 (0.45) | CTNNB1TDP1CYP1A2CYP2C19CYP2C9 | |
| SCHEMBL9676538 | 0.82 | TDP1 (0.53) | CTNNB1TDP1CYP1A2CYP2C19CYP2C9 | |
| SCHEMBL9678479 | 0.82 | TDP1 (0.53) | CTNNB1TDP1CYP1A2CYP2C19CYP2C9 | |
| SCHEMBL27081048 | 0.82 | CTNNB1 (0.49) | CTNNB1TDP1CYP1A2CYP2C19CYP2C9 | |
| SCHEMBL6444450 | 0.82 | TDP1 (0.53) | CTNNB1TDP1CYP1A2CYP2C19CYP2C9 | |
| SCHEMBL14720291 | 0.81 | CTNNB1 (0.47) | CTNNB1TDP1CYP1A2CYP2C19CYP2C9 | |
| SCHEMBL27627250 | 0.79 | CYP1A2 (0.46) | CTNNB1TDP1CYP1A2CYP2C19CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 88 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250084395-A1 | ENGINEERED NITRILASES FOR BIOCATALYSIS | KCAT ENZYMATIC PRIVATE LIMITED (IN) | 2025-03-13 | — | — | US | claimed |
| US-20250084395-A1 | ENGINEERED NITRILASES FOR BIOCATALYSIS | KCAT ENZYMATIC PRIVATE LIMITED (IN) | 2025-03-13 | — | — | US | disclosed |
| US-9828594-B2 | Nitrilases, nucleic acids encoding them and methods for making and using them | BASF ENZYMES LLC (US) | 2017-11-28 | — | — | US | disclosed |
| US-20160355801-A1 | NITRILASES, NUCLEIC ACIDS ENCODING THEM AND METHODS FOR MAKING AND USING THEM | VERENIUM CORPORATION | 2016-12-08 | — | — | US | disclosed |
| US-9315792-B2 | Nitrilases, nucleic acids encoding them and methods for making and using them | BASF ENZYMES LLC (US) | 2016-04-19 | — | — | US | disclosed |
| US-9315792-B2 | Nitrilases, nucleic acids encoding them and methods for making and using them | BASF ENZYMES LLC (US) | 2016-04-19 | — | — | US | disclosed |
| US-9217164-B2 | Nitrilases, nucleic acids encoding them and methods for making and using them | BASF ENZYMES LLC (US) | 2015-12-22 | — | — | US | disclosed |
| US-9217164-B2 | Nitrilases, nucleic acids encoding them and methods for making and using them | BASF ENZYMES LLC (US) | 2015-12-22 | — | — | US | disclosed |
| EP-2327766-B1 | Nitrilases | BASF ENZYMES LLC (US) | 2015-12-02 | — | — | EP | disclosed |
| EP-2327766-B1 | Nitrilases | BASF ENZYMES LLC (US) | 2015-12-02 | — | — | EP | disclosed |
| EP-1578910-A4 | NITRILASES | VERENIUM CORP (US) | 2008-06-04 | — | — | EP | disclosed |
| EP-1576108-A4 | NITRILASES, NUCLEIC ACIDS ENCODING THEM AND METHODS FOR MAKING AND USING THEM | VERENIUM CORP (US) | 2008-01-09 | — | — | EP | disclosed |
| EP-1578910-A2 | NITRILASES | DIVERSA CORPORATION (US) | 2005-09-28 | — | — | EP | disclosed |
| EP-1576108-A2 | NITRILASES, NUCLEIC ACIDS ENCODING THEM AND METHODS FOR MAKING AND USING THEM | DIVERSA CORPORATION (US) | 2005-09-21 | — | — | EP | disclosed |
| US-20040014195-A1 | Nitrilases, nucleic acids encoding them and methods for making and using them | DIVERSA CORPORATION (US) | 2004-01-22 | — | — | US | disclosed |
| US-20040002147-A1 | Nitrilases | DIVERSA CORPORATION | 2004-01-01 | — | — | US | disclosed |
| WO-2003097810-A2 | NITRILASES, NUCLEIC ACIDS ENCODING THEM AND METHODS FOR MAKING AND USING THEM | DIVERSA CORPORATION (US) | 2003-11-27 | — | — | WO | disclosed |
| US-20030124698-A1 | Which stereoselectively hydrolyze nitrites or cyanohydrins into acids and ammonia | DIVERSA CORPORATION | 2003-07-03 | — | — | US | disclosed |
| WO-2003000840-A2 | NITRILASES | DIVERSA CORPORATION (US) | 2003-01-03 | — | — | WO | disclosed |
| EP-0521827-A1 | Pharmacological active hydrazin derivatives and process for their preparation | CIBA-GEIGY AG (CH) | 1993-01-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040014195-A1 | Nitrilases, nucleic acids encoding them and methods for making and using them | RNGTT, NSUN2, NSUN3 | CTNNB1 4880/4885TDP1 34/4885CYP1A2 2975/4885 |
| US-20040002147-A1 | Nitrilases | RNGTT, DNTT, NOP2 | CTNNB1 4877/4885TDP1 49/4885CYP1A2 1608/4885 |
| US-20030124698-A1 | Which stereoselectively hydrolyze nitrites or cyanohydrins into acids and ammonia | NIT2, DNPH1, ASNS | CTNNB1 4451/4885TDP1 328/4885CYP1A2 1283/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.